Answer
It is unknown whether Fabhalta (iptacopan) passes into human breast milk; infant risk cannot be excluded, and a decision between stopping breast-feeding or stopping/avoiding Fabhalta must account for the benefits of breast-feeding for the child and treatment for the woman.
Sources for this answer
- FABHALTA 200 mg hard capsulesNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 4Document updated
Sources checked